How next-generation sequencing will change clinical practice

Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore discusses how next-generation sequencing (NGS) will change clinical practice in multiple myeloma (MM) and other cancers. According to Prof Chng, cancer treatment will move away from disease specific treatment to treatment based on molecular defects. There are still a number of gaps that need to be addressed before NGS can be applied in practice, such as the meaning of the individual genes and mutations and how doctors can interpret those to choose the right treatment.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland.